Poststent CT demonstrated adequate placement.
Stage III-B (T4 M0 N0) nonsmall cell lung cancer diagnosed in fall of [**2142**] treated with carboplatin/Taxol induction with low dose XRT.
Catanenial epilepsy treated in [**2134**].
PHYSICAL EXAM UPON ADMISSION:  Vital signs:  144/81, 100% on face mask, respiratory rate 34, pulse of 133, temperature 96.5.
LABORATORIES UPON ADMISSION:  White count is 7.1, hematocrit 31.7, platelets 584.
Sodium 136, potassium 4, chloride 98, bicarb 21, BUN 10, creatinine 0.4, glucose 144, calcium 9.1, magnesium 1.5, phosphate is 3.9.
Pleural fluid on [**5-3**] show reactive mesothelial cells and no malignant cells.
On [**2145-4-5**] chest CT scan status post stent showed stent in the right upper lobe bronchus marked with narrowing of origin in the right middle bronchus, moderate pericardial effusion, small partial loculated right pleural effusion, right middle lobe opacity, and diffuse emphysema.
A [**2145-5-21**] chest x-ray showed moderate large right pleural effusion, new consistent with compared with chest x-ray on [**2145-5-7**].
Pulmonary - Hemoptysis:  Patient was initially admitted to the Intensive Care Unit to keep her saturation above 92%.
Her hematocrit remained stable.
Her hematocrit remained stable and her hemoptysis decreased in frequency from seven episodes a day to just five episodes a day with sputum production consistent with a rust colored phlegm.
Infectious Disease:  The patient did have [**4-6**] blood cultures on [**2145-5-26**] and sputum that grew out MSSA.
Given that her Vancomycin trough was less than 10, her dosage was increased to 1250 mg IV bid of the Vancomycin.
A transesophageal echocardiogram was never done because the patient requested that she have some time to recover from her hemoptysis.
